Abnormalities of the innate immunity machinery make up a motley group of rare diseases named ‘autoinflammatory’, which are caused by mutations in genes involved in different immune pathways. Self-limited inflammatory bouts involving skin, serosal membranes, joints, gut and other districts of the human body burst and recur with variable periodicity in most autoinflammatory diseases (ADs), often leading to secondary amyloidosis as a long-term complication. Dysregulated inflammasome activity, overproduction of interleukin (IL)-1 or other IL-1-related cytokines and delayed shutdown of inflammation are pivotal keys in the majority of ADs. The recent progress of cellular biology has clarified many molecular mechanisms behind monogenic ADs, such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome (or ‘autosomal dominant familial periodic fever’), cryopyrin-associated periodic syndrome, mevalonate kinase deficiency, hereditary pyogenic diseases, idiopathic granulomatous diseases and defects of the ubiquitin-proteasome pathway. A long-lasting history of recurrent fevers should require the ruling out of chronic infections and malignancies before considering ADs in children.
Gene | Locus |
Protein | Inheritance | Main Manifestations and Complications | Available Treatments | |
---|---|---|---|---|---|---|
FMF | MEFV | 16p13.3 |
PYRIN or marenostrin | AR | serositis, limb pain or transient arthritis, erysipelas-like eruption on the legs, nonspecific skin manifestations (like urticaria, angioedema, erythema nodosum, vasculitis), risk of amyloidosis |
Cardinal Sign | Major Criteria | Minor Criteria |
---|---|---|
Colchicine, canakinumab, anakinra | ||
Fever of unknown origin that is documented to be daily (until 39 °C once a day with intermittent course) for at least 3 consecutive days and reoccurring over an observation period of at least two weeks |
|
PFAPA syndrome in children | Periodically recurring high fevers (with “clockwork” periodism at intervals of 4–6 weeks) + Onset before 5 years + Child’s complete wellness between attacks (with normal growth and no sequelae) |
At least 1 among: |
| Absence of respiratory infection-related symptoms | To rule out: |
| ||||||||||||||
PFAPA syndrome in adults | (at least 16-year-old) |
Recurrent fevers + Increased inflammatory parameters during febrile attacks + Symptom-free intervals |
At least 1 between: |
| To rule out: |
| ||||||||||||||
Eurofever/PRINTO classification criteria for | PFAPA syndrome | At least 7 out of the following 8 signs (either positive [from | a | to | d | ] or negative [from | e | to | h | ]): |
|
| ||||||||
|
| |||||||||||||||||||
TRAPS | TNFRSF1A | 12p13 |
TNFRSF1A, TNF receptor |
AD | severe migrating muscle pain, arthralgia or arthritis, serositis, painful orbital edema, painful conjunctivitis, risk of amyloidosis | Canakinumab, anakinra, corticosteroids | ||||||||||||||
FCAS | NLRP3 | 1q44 |
CRYOPYRIN | AD | cold-induced urticaria-like rashes, conjunctivitis, arthralgia | Anakinra, rilonacept, canakinumab | ||||||||||||||
MWS | cold-induced urticaria-like rash, conjunctivitis, episcleritis, arthralgia, neurosensorial deafness, risk of amyloidosis | |||||||||||||||||||
CINCA | migrating non-itchy urticaria-like rash, uveitis, papilledema, deforming arthritis involving large joints, aseptic chronic meningopathy, retinal dystrophy, neurosensorial deafness, risk of amyloidosis |
|||||||||||||||||||
MKD | MVK | 12q24 |
MEVALONATE KINASE | AR | fatigue, painful generalized lymph node enlargement, vomiting, diarrhea, abdominal pain, arthralgia, skin rashes of varying severity, oral and/or genital aphthosis, splenomegaly during flares |
Anti-inflammatory drugs, corticosteroids, anakinra ‘on demand’, canakinumab |
||||||||||||||
PAPA | PSTPIP1 | 15q24–25 |
PSTPIP1 (proline-serine- threonine phosphatase interacting protein 1) |
AD | sterile pyogenic arthritis, pyoderma gangrenosum, severe acne, skin abscesses, recurrent non-healing sterile ulcers | Corticosteroids, infliximab, anakinra, immunosuppressive agents |
||||||||||||||
MS | LPIN2 | 18p11.31 |
LIPIN2 (phosphatidate phosphatase) | AR | recurrent multifocal osteomyelitis, neutrophilic dermatosis, dyserythropoietic anemia | Corticosteroids, bisphosphonates, TNF-α inhibitors, IL-1 antagonists (anakinra) |
||||||||||||||
DIRA | IL1RN | 2q14.1 |
IL1RN (interleukin-1 receptor antagonist) |
AR | sterile multifocal osteomyelitis starting in the neonatal period, skin pustulosis, osteitis |
Anakinra | ||||||||||||||
BS | NOD2 (CARD15) | 16q12.1–13 |
NOD2 (nucleotide binding oligomerization domain containing 2) | AD | non-erosive granulomatous polyarthritis (‘boggy synovitis’ with painless effusion and cyst-like swelling of joints), granulomatous panuveitis, skin granulomatous rash | Corticosteroids, TNF-α inhibitors (infliximab), IL-1 antagonists, JAK inhibitors (tofacitinib) |
||||||||||||||
DITRA | IL36RN | 2q14.1 |
IL36RN (interleukin-36 receptor antagonist) |
AR | severe pustular psoriasis (generalized or limited to the distal part of limbs) | TNF-α inhibitors (adalimumab), IL-12/23 antagonists, IL-17 antagonists |
||||||||||||||
CAMPS | CARD14 | 17q25.3 |
CARD14 (caspase recruitment domain- containing protein 14) |
AD | psoriasis in a wide range of phenotypes | Methotrexate, corticosteroids, cyclosporine, phototherapy, acitretin, vitamin D analogs, TNF-α inhibitors, IL-12/23 antagonists, IL-17 antagonists |
||||||||||||||
ORAS | OTULIN | 5p15.2 |
OTULIN (deubiquitinase) | AR | fever starting in the neonatal period, neutrophilic dermatosis associated with panniculitis, growth retardation | TNF-α inhibitors | ||||||||||||||
HA20 | TNFAIP3 | (tumor necrosis factor alpha-induced protein 3, A20) |
AD | recurrent mucosal ulcerations of the oral cavity, gastrointestinal tube and urogenital tract, skin rashes, polyarthritis, uveitis, vasculitides, recurrent fevers, association with different autoimmune disorders (systemic lupus erythematosus, psoriatic arthritis, juvenile idiopathic arthritis, autoimmune hepatitis and Hashimoto thyroiditis) |
TNF-α inhibitors, colchicine | |||||||||||||||
TNFAIP3 | 6q23.3 |
FCAS2 | NLRP12 | 19q13.42 |
NLRP12 (nucleotide- binding oligomerization domain, leucine rich repeat and pyrin domain containing 12) |
AD | cold-induced rashes, joint pain, abdominal pain, sensorineural deafness, headache | Anakinra, TNF-α inhibitors, IL-6 antagonists (tocilizumab) |
||||||||||||
PRAAS | PSMB8 | PSMB8 (proteasome 20s subunit beta 8) |
AR | chronic atypical neutrophilic dermatosis, lipodystrophy, erythema nodosum-like panniculitis, abnormal growth of lips, muscular weakness and atrophy, severe joint contractures, basal ganglia calcifications, ear and nose chondritis, aseptic meningitis, conjunctivitis, hepatosplenomegaly, lymph node enlargement, arthralgia |
Corticosteroids, immunosuppressive agents, anakinra, IL-6 antagonists (tocilizumab), TNF-α inhibitors, dapsone, JAK inhibitors (baricitinib) |
|||||||||||||||
SAVI | STING1 | (TMEM173) 5q31.2 |
STING1 (stimulator of interferon genes protein 1) | AD | vasculopathy causing severe skin lesions on face, ears, nose and digits, resulting in ulcerations, necrosis or amputations, chronic interstitial lung disease |
JAK inhibitors (ruxolitinib) | ||||||||||||||
AGS | TREX1, | RNASEH2B, | RNASEH2C, | RNASEH2A, | SAMHD1, | ADAR, | IFIH1 | 3p21.31, 13q14.3, 11q13.1, 19p13.13, 20q11.23, 1q21.3, 2q24.2 |
Enzymes involved in the duplication, repair and recombination of nucleic acids | AR (AD for | IFIH1 | ) | leukoencephalopathy (mimicking transplacental infections), calcifications in cerebral and basal ganglia, dystonia, microcephaly, cognitive impairment, abnormal eye movements, glaucoma, livedo reticularis, digital chilblain lesions on hands and feet, hepatosplenomegaly, jaundice, silent positivity of autoantibodies |
No cure is available, corticosteroids and intravenous immunoglobulin may control systemic and organ inflammation |